Wall Street is positive on VolitionRX Ltd (VNRX). On average, analysts give VolitionRX Ltd a Strong Buy rating. The average price target is $6.925, which means analysts expect the stock to rise by 96.18% over the next twelve months.
That average ranking earns VolitionRX Ltd an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With VolitionRX Ltd Stock Today?
VolitionRX Ltd (VNRX) stock has gained 7.29% while the S&P 500 is lower by -0.01% as of 2:03 PM on Tuesday, Aug 4. VNRX has risen $0.24 from the previous closing price of $3.29 on volume of 237,360 shares. Over the past year the S&P 500 is higher by 15.80% while VNRX is lower by -4.59%. VNRX lost -$0.44 per share the over the last 12 months.
